Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Regional Breast Cancer Academic Day marks NHS retirement for Professor Adrian Harris

Department Research

This month the MRC Weatherall Institute of Molecular Medicine (WIMM) hosted the annual Regional Breast Cancer Academic Day, an event that brings together breast cancer teams from across the Thames Valley region. This year’s symposium involved the participation of over 70 attendees, including nurses, clinical trial managers, researchers and doctors.

In addition to the usual mix of internal and external speakers, this year's event was also an opportunity to highlight the contributions of Professor Adrian Harris, one of the organisers of the event. Professor Harris founded the Oxfordshire Breast Clinic in 1989. The event marked his official retirement from the clinic and from the National Health Service. Professor Harris will continue to lead a research group in the Department of Oncology.

The Harris group works on tumour angiogenesis and the role of Notch signalling, and hypoxia biology and its regulation. The ultimate aim of the research programme is to develop ways to improve the treatment of breast cancer and other tumour types, by blocking the blood supply to tumours. Professor Harris' group is one of the several research teams from the Department of Oncology within the WIMM, whose research focuses on cancer research. The Regional Breast Cancer Academic Day was sponsored by Eisai, Pierre Fabre, Novartis, Pfizer and Synthon.

Similar stories

Robert Watson Awarded ACP McElwain and Presidents Prize

Dr Robert Watson has won one of three McElwain and President's Prizes from the Association of Cancer Physicians for his DPhil work undertaken with Professor Ben Fairfax.

Prof Anna Schuh launches first private specialised haematology clinic and laboratory in sub-Saharan Africa.

SerenOx Africa aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility will also aim to provide early cancer detection for high-risk patients.

Professor Eileen Parkes appointed to lead Oxford’s Experimental Cancer Medicine Centre

Eileen Parkes, Associate Professor in Innate Tumour Immunology in the Department of Oncology, will lead the expansion of the centre’s programmes in early drug development and biomarker research.

Machine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation

In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.